Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Attempts To Recover After The Fall

January 26, 2022

After having gone through a fairly tough period, the Tonix Pharmaceuticals (NASDAQ:TNXP) stock managed to make a fairly strong recovery yesterday and ended up with gains of as much as 5%. That being said, investors need to note that despite the recovery yesterday, the stock is still down by as much as 13% over the past week. Trading Data On Tuesday, TNXP stock gained 4.83% to $0.2452 with more than…

Read More >>

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Stock Will Attempt To Bounce After The Fall

November 23, 2021

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) stock will be in focus on Tuesday as the stock is trading higher in the pre-market session. Trading Data On Monday, TNXP stock fell 3.84% to $0.46 with more than 24.80 million shares, compared to its average volume of 13.38 million shares. The stock has moved within a range of $0.4551 – 0.4909 after opening trade at $0.49. Publishes Study on TNX-3500 as an Antiviral…

Read More >>

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Continues to Trend Lower: Now What?

October 25, 2021

Investors in Tonix Pharmaceuticals (NASDAQ:TNXP) are probably going to be keeping tabs on the company’s stock this week since it did not have a particularly great time last week. The Tonix stock went down by as much as 5% last week and many would probably be hoping for a quick recovery. Market Action: On Friday, TNXP stock moved down 5.26% at $0.5535 with more than 19.81 million shares, compared to…

Read More >>

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Stock Extends Rally: Up 15% in a Week

October 19, 2021

When it comes to choosing stocks, it is perhaps a good idea to look into those stocks which may have recorded strong gains in the recent past and that principle brings us to the subject of Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP). The stock continued to be in focus among investors on Monday as it jumped by another 6% and thereby took its gains for the past week to as much…

Read More >>

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Stock Extends The Fall: Down 12% in a Month

September 24, 2021

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is down 12% in a month after announcing a research collaboration expansion with Columbia University. This research partnership focuses on the study of immune response to COVID-19 in healthy subjects that are asymptomatic or have recovered from the virus. Equally, it will study in vitro antibody and T cell responses to the COVID-19 causing virus, SARS-CoV-2.Most importantly, the research seeks to fill vital gaps in…

Read More >>

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Stock Sees Major Downtrend: Now What?

September 16, 2021

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) is a clinical-stage biopharma corporation that recently announced that the FDA (Food and Drug Administration) had given them an official written response from the pre-IND (Investigational New Drug) Type B meeting to develop its TNX-1800 product (live vaccine, recombinant horsepox) as a potential COVID-19 vaccine. Tonix Pharmaceuticals believes the response will provide the company with a path to several other agreements on the overall…

Read More >>

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Consolidates After The Big Fall

August 16, 2021

In recent weeks, Tonix Pharmaceuticals (NASDAQ:TNXP) has been in the middle of a fair bit of trouble and it has been reflected in the price action in its stock as well. The death spiral in the Tonix stock came about due to the massive setback in the interim analysis from the late stage clinical trials of one of its products. As a matter of fact, most experts believe that the…

Read More >>

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock In Serious under Pressure: Now What?

August 9, 2021

Investors of Tonix Pharmaceuticals (NASDAQ:TNXP) investors are not in the best state this week with devastating interim analysis from a  late-stage clinical trial likely to fail, the stock price has plummeted below $1. The firm’s late-stage programs infamously aim at hard conditions like post-traumatic stress disorder and Alzheimer’s disease, the firm is quite weak. Yet, daring investors may be looking at positive signs in the downturn. The company on July…

Read More >>

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Attempts To Bounce Back: A Value Buy?

August 6, 2021

Tonix Pharmaceuticals (NASDAQ:TNXP) stock is having a rough week after releasing a disappointing preliminary analysis from a late-stage clinical study that seems set to fail. The stock has since plunged below $1.Considering that Tonix’s other late-stage studies focus on difficult to treat conditions such as Alzheimer’s disease and PTSD, its outlook looks frail. However, bold investors may see the stumble as a chance to buy in, and they could be…

Read More >>

Is Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) Stock a Better Bet Now After The Recent Fall?

August 3, 2021

Based in New York, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP). is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800.However, recently the entire company is appearing quite fragile. The company has recently reported that it would not register any new patients with fibromyalgia with respect…

Read More >>